ReviewJournal of internal medicine2016
Precision medicine in pheochromocytoma and paraganglioma: current and future concepts.
Review in Journal of internal medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 54 citations in OpenAlex.
- Information quality and reliability of pheochromocytoma-related videos on tiktok and Kwai: a cross-sectional study.BMC urology · 2026Article
- [Neurofibromatosis 1-related tumors in pediatric patients].Problemy endokrinologii · 2025Article
- Esmolol's Role in Hemodynamic Management During Pheochromocytoma Surgery: A Comprehensive Review.Cureus · 2024Review
- Paraganglioma at the cerebellopontine angle: A case report and review of literature.Clinical case reports · 2024Article
- Pheochromocytoma: an updated scoping review from clinical presentation to management and treatment.Frontiers in endocrinology · 2024Article
- Multi-disciplinary surgery for simultaneous resection of multiple tumors in a patient with newly diagnosed metastatic pheochromocytoma/paraganglioma.Cancer pathogenesis and therapy · 2023Article
- Investigating the role of somatic sequencing platforms for phaeochromocytoma and paraganglioma in a large UK cohort.Clinical endocrinology · 2022Review
- From SGAP-Model to SGAP-Score: A Simplified Predictive Tool for Post-Surgical Recurrence of Pheochromocytoma.Biomedicines · 2022Article
- Review
- Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study.Cancers · 2021Article
- Clinical Perspectives of Theranostics.Molecules (Basel, Switzerland) · 2021Review
- Genotype-phenotype associations in PPGLs in 59 patients with variants in SDHX genes.Endocrine connections · 2020Article
- Pheochromocytoma and Paraganglioma in Children and Adolescents: Experience of the French Society of Pediatric Oncology (SFCE).Journal of the Endocrine Society · 2020Article
- Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature.Frontiers in endocrinology · 2020Review
- Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas.American journal of human genetics · 2019Article
- Transcriptome Analysis Reveals Significant Differences in Gene Expression of Malignant Pheochromocytoma or Paraganglioma.International journal of endocrinology · 2019Article
- Exosomal double-stranded DNA as a biomarker for the diagnosis and preoperative assessment of pheochromocytoma and paraganglioma.Molecular cancer · 2018Article
- Pheochromocytoma and paraganglioma: genotype versus anatomic location as determinants of tumor phenotype.Cell and tissue research · 2018Review
- Primary cardiac tumors associated with genetic syndromes: a comprehensive review.Pediatric radiology · 2018Review
- Clinical Syndromes and Genetic Screening Strategies of Pheochromocytoma and Paraganglioma.Journal of kidney cancer and VHL · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Pheochromocytoma and paraganglioma (PPGL) are rare diseases but are also amongst the most characterized tumour types. Hence, patients with PPGL have greatly benefited from precision medicine for more than two decades. According to current molecular biology and genetics-based taxonomy, PPGL can be divided into three different clusters characterized by: Krebs cycle reprogramming with oncometabolite accumulation or depletion (group 1a); activation of the (pseudo)hypoxia signalling pathway with increased tumour cell proliferation, invasiveness and migration (group 1b); and aberrant kinase signalling causing a pro-mitogenic and anti-apoptotic state (group 2). Categorization into these clusters is highly dependent on mutation subtypes. At least 12 different syndromes with distinct genetic causes, phenotypes and outcomes have been described. Genetic screening tests have a documented benefit, as different PPGL syndromes require specific approaches for optimal diagnosis and localization of various syndrome-related tumours. Genotype-tailored treatment options, follow-up and preventive care are being investigated. Future new developments in precision medicine for PPGL will mainly focus on further identification of driver mechanisms behind both disease initiation and malignant progression. Identification of novel druggable targets and prospective validation of treatment options are eagerly awaited. To achieve these goals, we predict that collaborative large-scale studies will be needed: Pheochromocytoma may provide an example for developing precision medicine in orphan diseases that could ultimately aid in similar efforts for other rare conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.